Misplaced Pages

Urtoxazumab: Difference between revisions

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
Browse history interactively← Previous editNext edit →Content deleted Content addedVisualWikitext
Revision as of 23:39, 13 November 2011 editCheMoBot (talk | contribs)Bots141,565 edits Updating {{drugbox}} (changes to verified fields - updated 'ChemSpiderID_Ref', 'UNII_Ref', 'ChEMBL_Ref', 'ChEBI_Ref', 'KEGG_Ref', 'StdInChI_Ref', 'StdInChIKey_Ref') per Chem/Drugbox validation (report [[Misplaced Pages talk:WikiProject_...← Previous edit Revision as of 13:23, 16 December 2011 edit undoAnypodetos (talk | contribs)Autopatrolled, Extended confirmed users, Pending changes reviewers, Rollbackers39,350 editsm Disambig Humanize, replaced: humanized monoclonal antibody → humanized monoclonal antibody using AWBNext edit →
Line 45: Line 45:
}} }}


'''Urtoxazumab''' is a ]d ] against ] caused by '']'', serotype ]. The drug is designed to bind to a ] of this bacterium, so that it can be more easily broken down and eliminated from the body.<ref>, ''World Health Organization''.</ref><ref>{{cite journal|year=2009|last1=López|first1=EL|last2=Contrini|first2=MM|last3=Glatstein|first3=E|last4=González Ayala|first4=S|last5=Santoro|first5=R|last6=Allende|first6=D|last7=Ezcurra|first7=G|last8=Teplitz|first8=E|last9=Koyama|first9=T|title=Safety and Pharmacokinetics of Urtoxazumab, a Humanized Monoclonal Antibody Against Shiga-Like Toxin 2 in Healthy Adults and Pediatric STEC- Infected Patients.|doi=10.1128/AAC.00343-09|journal=Antimicrobial agents and chemotherapy|pmid=19822704|volume=54|pages=239–243|issue=1|pmc=2798559}}</ref> '''Urtoxazumab''' is a ] against ] caused by '']'', serotype ]. The drug is designed to bind to a ] of this bacterium, so that it can be more easily broken down and eliminated from the body.<ref>, ''World Health Organization''.</ref><ref>{{cite journal|year=2009|last1=López|first1=EL|last2=Contrini|first2=MM|last3=Glatstein|first3=E|last4=González Ayala|first4=S|last5=Santoro|first5=R|last6=Allende|first6=D|last7=Ezcurra|first7=G|last8=Teplitz|first8=E|last9=Koyama|first9=T|title=Safety and Pharmacokinetics of Urtoxazumab, a Humanized Monoclonal Antibody Against Shiga-Like Toxin 2 in Healthy Adults and Pediatric STEC- Infected Patients.|doi=10.1128/AAC.00343-09|journal=Antimicrobial agents and chemotherapy|pmid=19822704|volume=54|pages=239–243|issue=1|pmc=2798559}}</ref>


== References == == References ==

Revision as of 13:23, 16 December 2011

Pharmaceutical compound
Urtoxazumab
Monoclonal antibody
TypeWhole antibody
SourceHumanized (from mouse)
TargetE. coli Shiga-like toxin II B subunit
Clinical data
ATC code
  • none
Identifiers
CAS Number
ChemSpider
Chemical and physical data
FormulaC6414H9934N1718O2010S40
Molar mass144.6 kDa g·mol
  (what is this?)  (verify)

Urtoxazumab is a humanized monoclonal antibody against diarrhoea caused by Escherichia coli, serotype O121. The drug is designed to bind to a toxin of this bacterium, so that it can be more easily broken down and eliminated from the body.

References

  1. International Nonproprietary Names for Pharmaceutical Substances (INN), World Health Organization.
  2. López, EL; Contrini, MM; Glatstein, E; González Ayala, S; Santoro, R; Allende, D; Ezcurra, G; Teplitz, E; Koyama, T (2009). "Safety and Pharmacokinetics of Urtoxazumab, a Humanized Monoclonal Antibody Against Shiga-Like Toxin 2 in Healthy Adults and Pediatric STEC- Infected Patients". Antimicrobial agents and chemotherapy. 54 (1): 239–243. doi:10.1128/AAC.00343-09. PMC 2798559. PMID 19822704.
Monoclonal antibodies for infectious disease and toxins
Fungal
Human
Viral
Human
Chimeric
Humanized
Bacterial
Human
Mouse
Chimeric
Humanized
Toxin
Human
Chimeric
Humanized


Stub icon

This antiinfective drug article is a stub. You can help Misplaced Pages by expanding it.

Stub icon

This monoclonal antibody–related article is a stub. You can help Misplaced Pages by expanding it.

Categories: